Drug-Drug Interaction Study of "CG100650" in Healthy Volunteers

This is a randomized, open label, multiple-dose, parallel study to compare PK and to evaluate Drug-Drug Interaction of CG100650 in healthy volunteers.

Total of 39 health volunteers will be randomized to receive either of Group A, B or C for 14 days (13 subjects each).

[Group A] Tramadol +Polmacoxib capsule [Group B] Polmacoxib capsule [Group C] Tramadol

Pharmacokinetic parameters will be evaluated as primary endpoint by changes from baseline;

Safety evaluation will be carried out by conducting vital sign, laboratory test, ECG, and collecting AE, CM by different Group.

Key Inclusion Criteria:

• Male or female aged ≥ 19 years and ≤ 50 years
• Without inborn or chronic disease and no symptoms in physical examination
• BMI(Body Mass Index) result ≥ 18kg/m 2 and ≤ 30kg/m2
• Adequate clinical laboratory test results as evidenced by Hematology, Hemostasis, Biochemistry, Urinalysis, Serology and so on
• Subject who understand the objective, method of the study and the characteristics of investigational drug and expected adverse events and provide written informed consent prior to study participation
• Negative pregnancy test(hCG) and agree to contraception during the trial

Key Exclusion Criteria:

• History of hypersensitivity to investigational products
• History of hypersensitivity or allergic reaction to sulfonamide.
• Patients with a history of asthma, acute rhinitis, nonspecific polyps, angioedema, urticaria or allergic reactions to aspirin or other nonsteroidal anti- inflammatory analgesics (including COX-2 inhibitors)
• Genetically galactose intolerance, lactose intolerance or Glucose-Galactose Malabsorption
• Any other reasons or situations that the investigator decides the patient is not eligible to participate the clinical trial.